Circulating tumor DNA dynamics in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer assessed using an ultrasensitive tumor-informed assay.

C H Barcenas¹, A Contreras², A Alexander³, H Lopez³, R Yu⁴, S Shete⁴, Y Chen⁵, C W Abbott⁵, K C Keough⁵, S M Boyle⁵, R O Chen⁵, D Tripathy³, V Valero³

¹Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: chbarcenas@mdanderson.org.

²Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.

³Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.

⁴Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.

⁵Department of Research and Development, Personalis, Fremont, USA.

PubMed DOI

Abstract

BACKGROUND: Circulating tumor DNA (ctDNA) in early breast cancer (EBC) is prognostic for distant relapses. The ctDNA dynamics in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative EBC, which is considered low-shedding, are challenging to track. We used an ultrasensitive assay to detect molecular residual disease (MRD) and its association with recurrence in this…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.